Plasminogen activator inhibitor-1 (PAI-1) is the main regulator of the fibrinolytic system.
血浆纤溶酶原激活物抑制剂(PAI) - 1是纤溶系统的主要调控因子。
Objective To assess the clinical significance of plasma t-PA, PAI-1 in acute cerebral infarction.
目的探讨血浆组织型纤溶酶原激活物(t -PA)及其抑制物(PAI - 1)在急性脑梗死发病中的意义。
Objective To investigate effects of fibrinolytic system upon deep venous thrombosis, focused on PLG, t-PA and PAI-1.
目的以纤溶酶原、t - PA和PAI - 1为轴心,探讨纤溶系统对深静脉血栓形成(DVT)的影响。
Conclusion In Vitro, high glucose suppresses human fibroblast cell proliferation and stimulates PAI-1 gene expression.
结论高糖可抑制成纤维细胞增殖,刺激PAI - 1的表达。
There were significant positive correlations between PAI-1 and WHR, TG, GSP, FINS and UA in the youth and middle-age group.
仅在青中年组与PAI-1表现相关性的指标是腰臀比(WHR)、甘油三酯(TG)、糖化血清蛋白(GSP)、血尿酸(UA)和FINS。
Objective To investigate the influence of rosiglitazone on blood lipids and plasma PAI-1 activity in type 2 diabetic patients.
目的观察罗格列酮对2型糖尿病患者血脂水平和血浆纤溶酶原激活物抑制剂1 (PAI - 1)活性的影响。
The expression of PAI-1 in liver tissue relates with activity HSCs. It reflects the development of liver fibrosis but not the degree.
肝组织中PAI - 1的表达与星状细胞活化有关,可反映肝纤维化的进展,但不能反映肝纤维化程度。
The experiments of inhibiting heterogeneous adhesion and invasion were used to observe the role of PAI-1 in PNC's metastasis and invasion.
使用异质粘附、侵袭抑制实验观察PAI-1在鼻咽癌细胞侵袭和转移过程中的作用。
The cardioprotective and renoprotective properties of some currently available drugs might be attributable in part to inhibition of PAI-1.
目前一些药物的心血管系统保护和肾脏保护的特点部分是源于其对PAI - 1活性的抑制作用。
This paper had summarized the structure, distribution, activity, expression of PAI-1 and the relation of its level with cerebral embolism.
文章概述了PAI - 1的结构、分布、活性及其表达,以及PAI - 1水平同脑血栓的关系。
Results There were significant differences int-PA and PAI-1 levels between the normal group and different types of cancer patients(P<0.05).
结果不同类型的恶性肿瘤患者t-PA及PAI-1与健康对照组比较差异有统计学意义(P<0.05)。
Objective To investigate the effect of simvastatin, ticlopidin and aspirin on the plasma plasminogen activitor inhibitor-l(PAI-1) contents in CHD patients.
目的研究辛伐他汀、抵克立得、阿司匹林对冠心病(CHD)患者血浆PAI-1含量的影响。
Method Plasminogen activator inhibitor-1(PAI-1) in 33 cases of diabetic nephropathy and 30 healthy controls were detected, and the test results were observed.
方法:检测33例糖尿病肾病患者及30例健康体检对照组血浆纤溶酶原激活物抑制物-1(PAI-1),观察检测结果。
AIM: To observe the effect of extract of Ginkgo biloba leaves on plasminogen activator inhibitor 1(PAI-1)and thromboxane B2(TXB-2)in type 2 diabetes mellitus(DM).
目的:观察银杏叶提取物对2型糖尿病病人纤溶酶原激活物抑制物1(PAI 1)及凝血烷B2(TXB 2 )的影响。
Plasminogen activator inhibitor-1 (PAI-1) is one of the important components of the plasma fibrinolytic system and plays an key role in maintaining its stability.
纤溶酶原激活物抑制物1 (PAI - 1)是血浆纤维蛋白溶解系统的重要组成物之一,对维持血浆纤溶系统的稳定起重要作用。
Conclusion Hypertension, increased plasma PAI-1 activity, fibrinogen level and plasma Hcy level are the important risk factors in the recurrent cerebral infarction.
结论:高血压、血纤溶系统活性升高、高水平纤维蛋白原、高同型半胱氨酸血症是脑梗死再发的重要危险因素。
The PAI-1 obvious correlates with the IS and CP. The increasement of PAI-1 causing reduction of serum plasminogen activator might be a intermediate process of IR and CBI.
脑梗塞血浆PAI-1活性增高与IS及C肽呈正相关,PAI-1活性增高导致血浆纤溶活性降低,可能是IR引起脑梗塞的中间环节。
Results: The activity of PAI-1 was higher and t-PA was lower in patients with coronary heart disease, and this difference is also found between Type a and Non Type a patients.
结果:冠心病患者比正常人群的PAI - 1活性上升,t -PA活性下降;这种改变在不同行为类型之间比较,A型行为类型比非a型行为类型的冠心病患者PAI - 1的活性升高而t - PA活性降低。
The neurological defect scores in patients with acute cerebral thrombosis were positively correlated with plasma and cerebrospinal fluid concentrations oft-PA and PAI-1 antigen.
脑血栓形成组病人神经功能缺损评分与血浆及脑脊液t -PA、PAI -1抗原含量呈正相关。
ObjectiveTo study the role and significance of plasminogen activator inhibitor-1(PAI-1) in renal fibrosis(RF) after damage and elucidate the molecular pathogenetic mechanisms of RF.
为探讨纤溶酶原激活物抑制因子1(PAI 1)在肾损伤后纤维化中的作用和意义,揭示其发病的分子病理机制。
Objective to study the effects of transient cerebral ischemic reperfusion (IR) and flunarizine on the expression of plasminogen activator inhibitor-1 (PAI-1) protein in brain tissue of gerbils.
目的研究沙鼠脑缺血再灌注后脑内1型纤溶酶原激活物抑制剂(PAI - 1)蛋白表达变化,以及西比灵干预的影响。
We have a study on the relationship between PAI-1 and the recent prognosis of patients with NSTE-ACS and the conventional factors being significant to the recent prognosis of patients with NSTE-ACS.
应用发色底物法测定所有患者血浆PAI-1的活性,并分析其与NSTE-ACS患者近期预后及预后相关因素之间的关系。
Objective To study the expression of plasminogen activator inhibitor-1(PAI-1) of the blood serum and plaques in atherosclerotic rabbits in order to explore the effect of PAI-1 on atherosclerosis (AS).
目的通过对动脉粥样硬化(AS)兔血清和粥样硬化斑块中纤溶酶原激活物抑制物-1(PAI-1)表达的研究,探讨PAI-1在AS中的作用。
Objective To investigate the relationship between the plasminogen activator inhibitor 1(PAI 1) promotor region gene polymorphism and cerebral stroke.
目的探讨纤溶酶原激活物抑制物- 1(PAI- 1)启动子区基因多态性与脑卒中的关系。
Objective To investigate effects of two proinflammatory cytokines on the production of plasminogen activator inhibitor 1(PAI 1) by human pleural mesothelial cells(HPMC).
目的研究前炎症细胞因子对人胸膜间皮细胞(HPMC)释放纤溶酶原激活物抑制剂(PAI 1)的诱导效应。
To investigate the changes of plasma PAI 1 activity and its gene polymorphism in cerebral infarction.
目的:探讨纤溶酶原激活物抑制物- 1 (PAI - 1)活性变化和其基因多态性对脑梗死及其再梗死发病的关系。
Conclusion:Pravastatin can not inhibit the secretion of PAI 1 in hepatic cells and the inhibition of hydroxymethylglutaryl coenzyme A reductase may not be related to the secretion of PAI 1.
结论:普伐他汀不能抑制肝细胞PAI- 1的分泌。羟甲基戊二酰辅酶A还原酶的抑制与PAI- 1分泌可能没有关系。
Objective to study the relationship between plasminogen activator inhibitor type 1 (PAI 1) and biological behaviour of hepatocellular carcinoma (HCC).
目的研究纤溶酶原激活物抑制剂(PAI1)与肝细胞癌(HCC)生物学特性的关系。
Objective to study the relationship between plasminogen activator inhibitor type 1 (PAI 1) and biological behaviour of hepatocellular carcinoma (HCC).
目的研究纤溶酶原激活物抑制剂(PAI1)与肝细胞癌(HCC)生物学特性的关系。
应用推荐